Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-05-03 | Mr. Liu received a B.S. from Shanghai Medical University and an M.Sc. from Dalhousie University. |
| 2022-04-28 | Mr. Liu received a B.S. from Shanghai Medical University and an M.Sc. from Dalhousie University. We believe Mr. Liu is qualified to serve on the Board because of his extensive executive leadership experience and his extensive experience in the life sciences industry in both sales and pharmaceutical development. |
| 2022-09-28 | Ye Liu Mr. Liu was appointed by Ocumension Therapeutics as their Investor Designee pursuant to the terms of the Share Purchase Agreement as filed with the SEC on Form 8-K, January 4, 2021. No mention of software or technical background. |
| 2023-04-28 | Mr. Liu received a B.S. from Shanghai Medical University and an M.Sc. from Dalhousie University. |
Data sourced from SEC filings. Last updated: 2026-03-05